Search results for "Lip"

showing 10 items of 8306 documents

Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry

2011

Morbus Fabry is a hereditary metabolic disorder with low prevalence and late clinical manifestation. A defect in the α-galactosidase gene leads to lysosomal accumulation of the glycolipid globotriaosylceramide (Gb3). Gb3 may be used for monitoring of enzyme replacement therapy (ERT), but diagnostic sensitivity is limited. Recently, globotriaosylsphingosine (lysoGb3) was introduced as a promising new marker with significantly better sensitivity. For Fabry diagnosis, clinical studies and possible therapy monitoring, we established a fast and reliable LC-MS/MS assay for quantification of lysoGb3 in human plasma. Protein precipitation and glycolipid extraction from EDTA plasma was performed usi…

AdultMaleAnalyteMolecular Sequence DataClinical BiochemistryGlobotriaosylceramideChemical FractionationTandem mass spectrometryBiochemistryHigh-performance liquid chromatographyAnalytical Chemistrychemistry.chemical_compoundTandem Mass SpectrometrymedicineHumansProtein precipitationDerivatizationChromatography High Pressure LiquidSphingolipidsChromatographyElutionTrihexosylceramidesReproducibility of ResultsCell BiologyGeneral Medicinemedicine.diseaseFabry diseaseCarbohydrate SequencechemistryCase-Control StudiesLinear ModelsFabry DiseaseFemaleGlycolipidsBiomarkersJournal of Chromatography B
researchProduct

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Ita…

2005

Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma. A total of 318 cycles were administered, with a median of 8 (range, 4-12) cycles per patient. Response rate (RR) was 45% (95% confidence interval (CI), 29%-62%), with 7 complete responses and 10 partial responses; furthermore, 12 patients showed a stable disease, so that a disease control was achieved in 29 (76%) patients. RR was greater among patients with performance status 0 (52%), without weight loss (52%), younger than 65 years (50%), and previou…

AdultMaleAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyLung NeoplasmsOrganoplatinum CompoundsColorectal cancerPhases of clinical researchAntineoplastic AgentsToxicologyDeoxycytidineGastroenterologyDisease-Free SurvivalCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansPharmacology (medical)CapecitabinePeritoneal NeoplasmsAgedAged 80 and overPharmacologyPerformance statusbusiness.industryCarcinomaLiver NeoplasmsMiddle Agedmedicine.diseaseOxaliplatinSurgeryOxaliplatinRegimenItalyOncologyFluorouracilLymphatic MetastasisFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer

2005

Abstract BACKGROUND AND AIMS: oxaliplatin in combination with folinic acid (FA) and infusional 5-fluorouracil (5-FU) has shown significant anti-tumor activity in gastric cancer patients (FOLFOX). Previous studies have shown that gemcitabine (GEM), a new fluorinated anti-metabolite, enhances the individual anti-tumor activity of either 5-FU or oxaliplatin. We have therefore designed a multi-center phase II trial in order to test a novel GEM+FOLFOX-4 regimen in patients with metastatic gastric cancer. METHODS: we enrolled 36 patients, 28 males and 8 females, with an average age of 64.4 years (range 37-78), who received bi-weekly treatment with GEM (1,000 mg/m2 on day 1), levo-FA (100 mg/m2 on…

AdultMaleAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsGastrointestinal Diseasesmedicine.drug_classfolinic acidmedicine.medical_treatmentLeucovorinAdenocarcinomaToxicologyDeoxycytidineAntimetaboliteGastroenterologyFolinic acidFOLFOXStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans5-fluorouracilPharmacology (medical)Infusions IntravenousAgedNeoplasm StagingPharmacologyChemotherapybusiness.industrygastric canceroxaliplatingemcitabineMiddle AgedHematologic DiseasesGemcitabineSurgeryOxaliplatinSurvival RateRegimenOncologyFluorouracilFemaleNeurotoxicity SyndromesFluorouracilbusinessmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

Homozygous familial hypercholesterolemia with severe involvement of the aortic valve—A sibling‐controlled case study on the efficacy of lipoprotein a…

2020

Background Homozygous familial hypercholesterolemia (hoFH) can cause severe atherosclerotic cardiovascular disease (ASCVD) in early infancy. Diagnosis and initiation of effective lipid-lowering therapy (LLT) are recommended as early as possible to prevent ASCVD-related morbidity and mortality. Methods The clinical courses of a pair of siblings with an identical hoFH genotype, who exhibited major similarities of their clinical phenotype were analyzed in a case-control fashion including the family. Results The older sibling was diagnosed with hoFH at the age of 4. Untreated LDL-cholesterol (LDL-C) was 17 mmol/L (660 mg/dL). LLT including lipoprotein apheresis (LA) was initiated and has been s…

AdultMaleAortic valvemedicine.medical_specialtyGenotypeBiopsyLipoproteinsFamilial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineXanthomatosisHumansMedicineSiblingChildAortaRetrospective StudiesFamily Healthbusiness.industryCholesterolSiblingsPCSK9HomozygoteMechanical Aortic ValveCholesterol LDLHematologyGeneral Medicinemedicine.diseaseLipidsPhenotypemedicine.anatomical_structurechemistryEchocardiographyAortic ValveCase-Control StudiesChild PreschoolAortic valve stenosisBlood Component RemovalFemalelipids (amino acids peptides and proteins)Proprotein Convertase 9business030215 immunologymedicine.drugJournal of Clinical Apheresis
researchProduct

Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family.

2011

Abstract Background Autosomal dominant hypercholesterolemias (ADHs) are characterised by increased plasma levels of total and LDL cholesterol, predisposing to premature atherosclerosis. ADHs comprise several diseases with undistinguishable phenotype, caused by mutations in different genes: LDLR, APOB and PCSK9. Genetic studies are usually performed in patients with altered cholesterol levels. However, some persons carrying pathogenic mutations are normocholesterolemic and there are no further studies about this subject. We have studied the frequency of families and individuals carrying ADH mutations who do not present the disease in Spanish population. Methods We have analysed genes known t…

AdultMaleApolipoprotein BAdolescentFamilial hypercholesterolemiaBiologymedicine.disease_causeHyperlipoproteinemia Type IIChlorocebus aethiopsmedicineAnimalsHumansGenetic TestingChildGeneGenetic testingAgedApolipoproteins BGeneticsFamily HealthMutationmedicine.diagnostic_testurogenital systemPCSK9Serine EndopeptidasesCholesterol LDLSequence Analysis DNAMiddle Agedmedicine.diseasePenetrancePhenotypePedigreePhenotypeMutagenesisSpainApolipoprotein B-100COS CellsMutationbiology.proteinFemaleProprotein ConvertasesProprotein Convertase 9Cardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsAtherosclerosis
researchProduct

Acute Myocardial Infarction and Proinflammatory Gene Variants

2007

We identified four genetic risk sets for acute myocardial infarction (AMI) from information on functional gene variants that favor inflammation or modulate cholesterol metabolism: IL6 -174 G/C, TNF -308 G/A, IL10 -1082 G/A, SERPINA3 -51 G/T, IFNG +874 T/A, HMGCR -911 C/A, and APOE ε2/3/4; 316 patients and 461 healthy subjects, all Italian. Putative risk alleles are shown underlined. The sets were identified using grade-of-membership analysis. Membership scores in the sets are automatically generated for individuals. The ''low intrinsic risk'' set had alleles that downregulate inflammation and cholesterol synthesis (IL6, TNF, ILl0, HMGCR). ''AMI across a broad age range'' carried multiple pr…

AdultMaleApolipoprotein EAdolescentMyocardial InfarctionGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokinePathogenesischemistry.chemical_compoundApolipoproteins EHistory and Philosophy of SciencemedicineHumansGenetic Predisposition to DiseaseMyocardial infarctionAge of OnsetAlleleAllelesSerpinsAgedAged 80 and overbusiness.industryCholesterolGeneral NeuroscienceMiddle Agedmedicine.diseaseMiddle ageInterleukin 10CholesterolchemistryAMI Grade of Membership Genetic profile IL6 -174 G/C TNF -308 G/A IL10 -1082 G/A SERPINA3 -51 G/T IFNG +874 T/A HMGCR -911 C/A APOE ε2/3/4Acute DiseaseImmunologyCytokinesFemaleHydroxymethylglutaryl CoA Reductaseslipids (amino acids peptides and proteins)businessAnnals of the New York Academy of Sciences
researchProduct

Apolipoprotein E Genotypic Frequencies Among Down Syndrome Patients Imply Early Unsuccessful Aging for ApoE4 Carriers

2007

Down syndrome (DS) might be considered a model for unsuccessful and early aging, possibly accelerated for those who carry the APOE4 allele associated with common age-related diseases, e.g., Alzheimer's disease and a poor prognosis after acute myocardial infarction, causing lower ApoE4 frequencies among the very old in general populations. We compared ApoE genotypic frequencies found for healthy adults (n = 211, age 90) to those found for DS patients (n = 106, mean age 9 years), all living in western Sicily. We found that the frequency of the ApoE23 genotype increased with age among the healthy adults (8.5%, 6.4%, 19.7%; p = 0.024) while ApoE34 frequency decreased (16.1%, 12.6%, 4.1%; p = 0.…

AdultMaleApolipoprotein EAgingmedicine.medical_specialtyPathologyDown syndromeAdolescentGenotypeChromosomes Human Pair 21Down syndromeApolipoprotein E4DiseaseBiologyGastroenterologySettore MED/38 - Pediatria Generale E SpecialisticaInternal medicineGenotypemedicineHumansSettore MED/05 - Patologia ClinicaMyocardial infarctionChildapolipoprotein EInfantSequence Analysis DNAPrognosismedicine.diseaseGenotype frequencyAgeingChild PreschoolFemaleGeriatrics and GerontologyChromosome 21Rejuvenation Research
researchProduct

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis

2019

Background: The course of multiple sclerosis (MS) shows substantial inter-individual variability. The underlying determinants of disease severity likely involve genetic and environmental factors. Objective: The aim of this study was to assess the impact of APOE and HLA polymorphisms as well as smoking and body mass index (BMI) in the very early MS course. Methods: Untreated patients ( n = 263) with a recent diagnosis of relapsing-remitting (RR) MS or clinically isolated syndrome underwent standardized magnetic resonance imaging (MRI). Genotyping was performed for single-nucleotide polymorphisms (SNPs) rs3135388 tagging the HLA-DRB1*15:01 haplotype and rs7412 (Ɛ2) and rs429358 (Ɛ4) in APOE. …

AdultMaleApolipoprotein EMultiple SclerosisAdolescentPolymorphism Single NucleotideBody Mass IndexYoung Adult03 medical and health sciencesApolipoproteins E0302 clinical medicineAtrophyMedizinische FakultätmedicineHumansSNPGenetic Predisposition to Disease030212 general & internal medicineddc:610Risk factorHLA-DRB1Agedbusiness.industryMultiple sclerosisSmokingNeurodegenerationBrainMiddle Agedmedicine.diseaseNeurologyImmunologyFemaleNeurology (clinical)AtrophybusinessBody mass index030217 neurology & neurosurgeryHLA-DRB1 Chains
researchProduct

Saturated fat intake and alcohol consumption modulate the association between the APOE polymorphism and risk of future coronary heart disease: a nest…

2011

The association is still not clear between the common APOE polymorphism and coronary heart disease (CHD) risk, nor its modulation by diet. Thus, our aim was to study the association between the APOE genotypes and incident CHD and how dietary fat and alcohol consumption modify these effects. We performed a nested case-control study in the Spanish European Prospective Investigation into Cancer and Nutrition cohort. Healthy men and women (41,440, 30-69 years) were followed up over a 10-year period, with the incident CHD cases being identified. We analyzed 534 incident CHD cases and 1123 controls. APOE, dietary intake and plasma lipids were determined at baseline. The APOE polymorphism was sign…

AdultMaleApolipoprotein Emedicine.medical_specialtyAlcohol DrinkingGenotypeEndocrinology Diabetes and MetabolismSaturated fatClinical BiochemistryPopulationCoronary DiseaseBiochemistryGastroenterologyWhite PeopleApolipoproteins ERisk FactorsInternal medicineOdds RatiomedicineHumansLongitudinal StudieseducationMolecular BiologyAllelesAgededucation.field_of_studyPolymorphism GeneticNutrition and Dieteticsbusiness.industryFatty AcidsCase-control studyCholesterol LDLOdds ratioMiddle AgedDietEuropean Prospective Investigation into Cancer and NutritionEndocrinologySpainCase-Control StudiesMultivariate AnalysisNested case-control studySaturated fatty acidRegression AnalysisFemalebusinessThe Journal of Nutritional Biochemistry
researchProduct

Prevalence of Apolipoprotein E Alleles in Healthy Subjects and Survivors of Ischemic Stroke

1998

Background and Purpose —The ε4 allele of the apolipoprotein E (apoE) has been related to the occurrence of myocardial infarction, but its association with ischemic stroke is controversial. We have evaluated the relation between apoE alleles and the occurrence of cerebrovascular ischemia. Methods —The apoE ε genotypes of 100 patients with a documented history of ischemic stroke without clinically apparent dementia (stroke+) and 108 subjects without such history (stroke−) were determined. The relative frequency of the apoE alleles and genotypes was estimated in 398 healthy subjects aged <40 years from the same ethnic background. Results —The frequency of the apoE ε4 allele in stroke+ (0.1…

AdultMaleApolipoprotein Emedicine.medical_specialtyGastroenterologyBrain IschemiaCentral nervous system diseaseApolipoproteins EReference ValuesRisk FactorsInternal medicineOdds RatiomedicineHumansSurvivorsMyocardial infarctionRisk factorAlleleStrokeAllelesAgedAged 80 and overAdvanced and Specialized Nursingbusiness.industryDementia VascularHomozygoteCase-control studyMiddle Agedmedicine.diseaseThrombosisSurgeryItalyCase-Control StudiesFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke
researchProduct